Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 16/20 | 0.69 |
| ▸ | QPCT | Q16769 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4989024 | 1.00 | APP (0.69) | APPQPCTKDM4EMAPTMAOA | |
| SCHEMBL14433381 | 0.85 | APP (0.69) | APPKDM4EMAPTMAOAMAOB | |
| SCHEMBL10144983 | 0.85 | APP (0.69) | APPKDM4EMAPTMAOAMAOB | |
| SCHEMBL9976004 | 0.83 | KDM4E (0.72) | APPKDM4EMAPTMAOAMAOB | |
| SCHEMBL4987282 | 0.83 | APP (0.65) | APPKDM4EMAPTMAOAMAOB | |
| SCHEMBL10144896 | 0.83 | APP (0.65) | APPKDM4EMAPTMAOAMAOB | |
| SCHEMBL4987371 | 0.83 | MAOA (0.74) | APPKDM4EMAPTMAOAMAOB | |
| SCHEMBL10144902 | 0.83 | MAOA (0.74) | APPKDM4EMAPTMAOAMAOB | |
| SCHEMBL7575776 | 0.83 | MAPT (0.71) | APPKDM4EMAPTMAOAMAOB | |
| SCHEMBL7575770 | 0.83 | MAPT (0.71) | APPKDM4EMAPTMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8192717-B2 | Flavone derivative, chalcone derivative, styrylchromone derivative, or a coumarin derivative with high binding specificity to an amyloid beta protein, high permeability to a blood-brain barrier, and ability to rapidly disappear from sites other than cerebral senile plaque; also drug screening | NAGASAKI UNIVERSITY (JP) | 2012-06-05 | — | — | US | disclosed |
| US-20080131367-A1 | Composition For Diagnosing Amyloid-Related Diseases | Mori, Hiroshi (JP) | 2008-06-05 | — | — | US | disclosed |
| EP-1815872-A1 | COMPOSITION FOR AMYLOID-ASSOCIATED DISEASE DIAGNOSIS | Nagasaki University (JP) | 2007-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080131367-A1 | Composition For Diagnosing Amyloid-Related Diseases | APP, APBA1, FABP7 | APP 1/4885QPCT 1735/4885KDM4E 3076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.